![]() |
![]() |
Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
Bank Loan Ratings | 16.25 | ACUITE BB | Downgraded | Issuer not co-operating* | - |
Bank Loan Ratings | 2.00 | - | ACUITE A4+ | Reaffirmed | Issuer not co-operating* |
Total Outstanding | 18.25 | - | - |
Total Withdrawn | 0.00 | - | - |
* The issuer did not co-operate; based on best available information. |
Rating Rationale |
Acuité has downgraded the long-term rating to ‘ACUITE BB’ (read as ACUITE double B) from 'ACUITE BB+' (read as ACUITE double B plus) and reaffirmed the short term rating of ‘ACUITE A4+’ (read as ACUITE A four plus) on the Rs.18.25 Crore bank facilities of Ion Healthcare Private Limited on account of information risk. The rating continues to be flagged as “Issuer Not-Cooperating” and is based on the best available information. |
About the Company |
Ion Healthcare Private Limited (IHPL) was incorporated in 2004 and subsequently acquired by Mr. B. K. Agarwal, Mr. Sanjeev Agarwal and Mrs. Vaishali Agarwal in 2014 presently being controlled and managed by Sh. Atul Kumar Agrawal & Sh. Leela Krishna Varshney in Baddi, Himachal Pradesh. The company is engaged in the manufacturing of generic drugs, ointments, ophthalmic drops, syrups, injections and among other pharmaceutical products. The company has an installed capacity of 430 million tablets, 135 million capsules, 18 million ointments and 25 million syrups. |
Unsupported Rating |
Not Applicable |
Non-cooperation by the issuer/borrower: |
Acuité has been requesting for data, information and undertakings from the rated entity for conducting surveillance & review of the rating. However, the issuer/borrower failed to submit such information before the due date. |
Limitation regarding information availability |
Rating Sensitivity |
"No information provided by the issuer / available for Acuite to comment upon." |
Liquidity Position |
"No information provided by the issuer / available for Acuite to comment upon." |
Outlook |
Not Applicable |
Other Factors affecting Rating |
None |
Particulars | Unit | FY 24 (Actual) | FY 23 (Actual) |
Operating Income | Rs. Cr. | 50.77 | 39.83 |
PAT | Rs. Cr. | 0.14 | 0.04 |
PAT Margin | (%) | 0.27 | 0.09 |
Total Debt/Tangible Net Worth | Times | 1.39 | 1.46 |
PBDIT/Interest | Times | 1.93 | 1.83 |
Status of non-cooperation with previous CRA |
Not Applicable |
Any other information |
None |
Applicable Criteria |
• Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm • Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm |
Note on complexity levels of the rated instrument |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
* The issuer did not co-operate; based on best available information. |
Contacts |
About Acuité Ratings & Research |
© Acuité Ratings & Research Limited. All Rights Reserved. | www.acuite.in |